<DOC>
	<DOCNO>NCT02063113</DOCNO>
	<brief_summary>The aim study determine whether presence vulnerability detect geriatrician associate treatment discontinuation older patient . During comprehensive geriatric assessment realize decision-treatment , follow data record impact therapeutic change also analyse : comorbidity , age , depression , functional status , cognitive impairment malnutrition .</brief_summary>
	<brief_title>Vulnerability Therapeutic Changes Older Patients With Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients age 70 year old Patients refer assessment newly diagnose multiple myeloma Patients initial therapy propose either melphalanprednisonethalidomide melphalanprednisonebortezomib include phase 3 trial . Patients provide inform write consent Patients refuse study Patients wo n't therapy Patients ca n't respond geriatric assessment severe cognitive disorder Patients legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multiple myeloma ,</keyword>
	<keyword>Older patient ,</keyword>
	<keyword>Treatment ,</keyword>
	<keyword>Geriatric assessment</keyword>
</DOC>